Mwyngil Therapeutics In-Licenses GPR75 Modulators
Slice of Healthcare Team
11/07/2025
Key highlights
- In-licensing of GPR75 modulators from Expert Systems Inc.
- Strengthens portfolio in cardiometabolic and chronic inflammatory diseases.
- GPR75 reverse agonists offer novel approaches to obesity and T2D.
- Preclinical studies show promising results in weight control and insulin sensitivity.
- Collaboration enhances metabolic and inflammatory pathway modulation.
Source: PR Newswire
Notable Quote
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
